Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 418

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes

Open access
Kirchhof, Paulus, Toennis, Tobias, Goette, Andreas, Camm, A. John, Diener, Hans Christoph, Becher, Nina, Bertaglia, Emanuele, Blomstrom Lundqvist, Carina, Borlich, Martin, Brandes, Axel, Cabanelas, Nuno, Calvert, Melanie, Chlouverakis, Gregory, Dan, Gheorghe-Andrei, de Groot, Joris R., Dichtl, Wolfgang, Kravchuk, Borys, Lubiński, Andrzej, Marijon, Eloi, Merkely, Béla, Mont, Lluís, Ozga, Ann-Kathrin, Rajappan, Kim, Sarkozy, Andrea, Scherr, Daniel, Sznajder, Rafał, Velchev, Vasil, Wichterle, Dan, Sehner, Susanne, Simantirakis, Emmanuel, Lip, Gregory Y.H., Vardas, Panos, Schotten, Ulrich, Zapf, Antonia·2023·New England Journal of Medicine

Abstract

BACKGROUND: Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and brief. Whether the occurrence of AHREs in patients without atrial fibrillation (as documented on a conventional electrocardiogram [ECG]) justifies the initiation of anticoagulants is not known. METHODS: We conducted an event-driven, double-blind, double-dummy, randomized trial involving patients 65 years of age or older who had AHREs lasting for at least 6 minutes and who had at least one additional risk factor for stroke. Patients were randomly assigned in a 1:1 ratio to receive edoxaban or placebo. The primary efficacy outcome was a composite of cardiovascular death, stroke, or systemic embolism, evaluated in a time-to-event analysis. The safety outcome was a composite of death from any cause or major bleeding. RESULTS: The analysis population consisted of 2536 patients (1270 in the edoxaban group and 1266 in the placebo group). The mean age was 78 years, 37.4% were women, and the median duration of AHREs was 2.8 hours. The trial was terminated early, at a median follow-up of 21 months, on the basis of safety concerns and the results of an independent, informal assessment of futility for the efficacy of edoxaban; at termination, the planned enrollment had been completed. A primary efficacy outcome event occurred in 83 patients (3.2% per patient-year) in the edoxaban group and in 101 patients (4.0% per patient-year) in the placebo group (hazard ratio, 0.81; 95% confidence interval [CI], 0.60 to 1.08; P = 0.15). The incidence of stroke was approximately 1% per patient-year in both groups. A safety outcome event occurred in 149 patients (5.9% per patient-year) in the edoxaban group and in 114 patients (4.5% per patient-year) in the placebo group (hazard ratio, 1.31; 95% CI, 1.02 to 1.67; P = 0.03). ECG-diagnosed atrial fibrillation developed in 462 of 2536 patients (18.2% total, 8.7% per patient-year). CONCLUSIONS: Among patients with AHREs detected by implantable devices, anticoagulation with edoxaban did not significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo, but it led to a higher incidence of a composite of death or major bleeding. The incidence of stroke was low in both groups. (Funded by the German Center for Cardiovascular Research and others; NOAH-AFNET 6 ClinicalTrials.gov number, NCT02618577; ISRCTN number, ISRCTN17309850.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2303062

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 418

Metadata

Authors
Kirchhof, P., Toennis, T., Goette, A., Camm, A. J., Diener, H. C., Becher, N., Bertaglia, E., Blomstrom Lundqvist, C., Borlich, M., Brandes, A., Cabanelas, N., Calvert, M., Chlouverakis, G., Dan, G.-A., de Groot, J. R., Dichtl, W., Kravchuk, B., Lubiński, A., Marijon, E., Merkely, B., Mont, L., Ozga, A.-K., Rajappan, K., Sarkozy, A., Scherr, D., Sznajder, R., Velchev, V., Wichterle, D., Sehner, S., Simantirakis, E., Lip, G. Y. H., Vardas, P., Schotten, U., & Zapf, A.
Venue
New England Journal of Medicine
Published
2023-09-28
Volume
389
Issue
13
Pages
1167-1179
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4386153792
Cited by
418
References
29
FWCI
73.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. https://app.cochat.ai/papers/10.1056/nejmoa2303062
The paper
Kirchhof, P., Toennis, T., Goette, A., Camm, A. J., Diener, H. C., Becher, N., Bertaglia, E., Blomstrom Lundqvist, C., Borlich, M., Brandes, A., Cabanelas, N., Calvert, M., Chlouverakis, G., Dan, G.-A., de Groot, J. R., Dichtl, W., Kravchuk, B., Lubiński, A., Marijon, E., . . . Zapf, A. (2023). Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2303062

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.